Background {#Sec1}
==========

Carbapenems are a highly potent class of antibiotics used to treat infections caused by multidrug resistant (MDR) Gram negative bacteria. However, the effectiveness of these antibiotics is currently being threatened by the emergence of carbapenem resistant bacteria \[[@CR1], [@CR2]\]. Carbapenemases are the main mechanism by which resistance to carbapenems occurs \[[@CR1], [@CR3]--[@CR5]\], and they belong to three of the four β-lactamase classes A, B and D \[[@CR1]--[@CR5]\]. Class D carbapenemases are the OXA-β-lactamases \[[@CR4]\], further subdivided into various sub-groups mainly *bla*~OXA-23~, *bla*~OXA-24/40~, *bla*~OXA-58~, *bla*~OXA-48~, *bla*~OXA-51~ and *bla*~OXA-143~ \[[@CR1], [@CR4]\]. These OXA-type β-lactamases occur widely in *Acinetobacter* with the most abundant being *bla*~OXA-51~, which is chromosomally encoded hence intrinsic to these species but it may confer resistance to carbapenems when its expression is up-regulated by genetic re-organization \[[@CR1], [@CR4], [@CR6]\]. Class B carbapenemases are also known as the metallo-β-lactamases (MBLs) \[[@CR1], [@CR3]\]; they are mostly encoded by integron-borne mobile gene cassettes and hence, they are transferable amongst various bacteria via horizontal gene transfer mechanisms notably conjugation \[[@CR3]\]. Class A carbapenemases include the *Klebsiella pneumoniae* carbapenemase (KPC) family that can be plasmid encoded or chromosomal \[[@CR2], [@CR5]\].

The hospital environment, mostly the intensive care units (ICUs), is a hotspot of antimicrobial resistance and source of MDR bacterial infections \[[@CR7]\], particularly infections involving *Acinetobacter* species and *Pseudomonas aeruginosa*. The aim of this study was to determine the prevalence of carbapanem resistant *Acinetobacter baumannii* (CRAB) and carbapenem resistant *Pseudomonas aeruginosa* (CRPA) in clinical specimens from the Mulago Hospital ICU. Also, carriage of carbapenemase encoding genes and class 1 integrons was investigated, as well as mobility potential of the genetic elements among CRPA and CRAB isolates.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

This was a cross sectional study conducted at Mulago National Referral Hospital in Kampala, Uganda. Culturing and other laboratory procedures were performed at the laboratories of the Departments of Medical Microbiology and Immunology & Molecular Biology, Makerere University College of Health Sciences.

Samples {#Sec4}
-------

The bacteria investigated were isolated from clinical specimens referred by physicians for diagnostic testing (mainly culturing and identification of bacterial pathogens) in the period between 2015 and 2017. During this period, the Clinical Microbiology Laboratory processed clinical specimens from a total of 9269 patients for isolation of CRAB and CRPA. The specimens included blood, tracheal aspirates, ear swabs, catheter tips, sputum, pus swabs, throat swabs etc. Majority (78%) of the specimens yielding CRAB and CRPA isolates were from the ICU while 20% were from the Ear Nose & Throat (ENT) department. The Burns unit contributed the remaining 2% of the isolates.

Culturing, identification and drug susceptibility testing {#Sec5}
---------------------------------------------------------

Culturing and identification of isolates to species level was performed as described previously \[[@CR1]\]. Briefly, presumptive identification of the isolates was based on colony morphology, Gram staining characteristics and biochemical properties. Biochemical tests included triple sugar iron (TSI), Sulphur indole motility test (SIM), as well as citrate, urease and oxidase tests. *Pseudomonas aeruginosa* colonies were identified by their spreading pattern, serrated edges, fruity sweet-grape smell and bright green color. In addition, a negative TSI, positive catalase and oxidase tests and growth at 42 °C were also used to identify *Pseudomonas aeruginosa*. *Acinetobacter* isolates were identified based on negative oxidase and glucose fermentation tests, negative catalase and motility tests and their inability to grow under anaerobic conditions. Further, to identify *Acinetobacter baumannii*, PCR-detection of the *bla*~OXA-51~ gene intrinsic to this species was performed \[[@CR1], [@CR6], [@CR8]\].

Following isolate identification, drug susceptibility testing was performed using the Kirby Bauer disk diffusion method on Mueller Hinton agar (MHA) (BiolabZrt Budapest, Hungary), as recommended by the Clinical Laboratory Standards Institute (CLSI, 2014) and elsewhere \[[@CR1], [@CR9], [@CR10]\]. Briefly, three colonies of the test isolate were emulsified into sterile saline and the resulting suspension adjusted to turbidity of 0.5 McFarland. Antibiotic discs (BiolabZrt Budapest, Hungary) screened against the isolates were imipenem (10 μg), meropenem (10 μg), piperacillin/tazobactam (100 μg /10 μg), colistin (10 μg), gentamicin (10 μg), amikacin (30 μg), ciprofloxacin (5 μg), cefepime (30 μg), and ceftazidime (30 μg). Interpretation of susceptibility testing results was according to CLSI guidelines (2014). Quality control procedures were done using *Pseudomonas aeruginosa* ATCC 27853 and *Escherichia coli* ATCC 35218/25922 \[[@CR1], [@CR9], [@CR10]\].

Carbapenemase assays {#Sec6}
--------------------

Phenotypic screening for carbapenemase activity was done using the Modified Hodge Test (MHT). Additionally, combination disc tests, imipenem-EDTA and boronic acid inhibition tests, were used to screen for MBL and KPC production respectively, as described previously \[[@CR1], [@CR9], [@CR11]\]. In the MHT assay, a 1:10 dilution of the indicator strain (*Klebsiella pneumoniae* ATCC 700603 or *E. coli* ATCC 25922) was made by diluting 0.5 ml of culture (0.5 McFarland) to 5 ml with sterile normal saline. Then, a lawn culture (1,10 dilution) was streaked onto a MHA plate using a sterile swab. A 10 μg meropenem disk was placed in the center of the test area on the MHA plate, and test isolates streaked in a straight line from the edge of the disk to the edge of the plate. *Klebsiella pneumoniae* ATCC BAA-1705 and *Klebsiella pneumoniae* ATCC BAA-1706 were used as positive and negative controls, respectively \[[@CR1], [@CR12]--[@CR14]\]. Furthermore, isolates that were found to be non-susceptible to imipenem or meropenem were also screened for MBL activity. In the MBL assay, overnight liquid cultures of the test isolates (adjusted to a 0.5 McFarland) were streaked on a MHA plate. Two discs of imipenem (10 μg) were placed 15 mm apart (center-to-center); of the two discs, one was impregnated with 10 μl of 0.5 M EDTA to achieve a disc content of 1.5 mg EDTA. Following this, incubation was done at 37 °C, overnight. An increase in inhibition zone diameter by ≥5 mm in the EDTA-supplemented disc was interpreted as positive for MBL production \[[@CR1]\]. Isolates that were positive were also screened for KPC production. In this test, a 10 μg meropenem disc and another 10 μg meropenem disc containing 3- AminoPhenyl boronic Acid (3-APBA) (300 μg/ml) (Tokyo Chemical Co. Ltd., Japan) were placed 20 mm apart, center-to-center. An increase in inhibition zone diameter by ≥5 mm around the combination disc compared to the meropenem disc alone was considered positive for KPC production \[[@CR11]\].

Detection of carbapenemase genes and class 1 integrons {#Sec7}
------------------------------------------------------

Molecular assays to determine carriage of carbapenemase encoding genes among CRAB and CRPA were performed as described previously \[[@CR1], [@CR15], [@CR16]\]. The carbapenemase genes screened for included MBL encoding genes (*bla*~IMP~*, bla*~VIM~*, bla*~SPM~*, bla*~NDM~ & *bla*~KPC~) and OXA-type genes (*bla*~OXA-23~, *bla*~OXA-24~ & *bla*~OXA-58~). Primers used in PCRs and amplicon analysis were described previously \[[@CR1], [@CR17]\].

Conjugation and identification of transconjugants {#Sec8}
-------------------------------------------------

Conjugation experiments were performed as described previously \[[@CR18], [@CR19]\] using CRAB/CRPA as donors and *E. coli* J53 (F− met pro Azi^r^) which is resistant to sodium azide, as a recipient. Additional donor characteristics included co-carriage of class 1 integrons and *bla*~VIM~ gene. CRBA/CRPA (donor) and *E. coli* J53 (recipient) were mixed in a ratio of 10:1 (donor:recipient) in Luria Bertani broth and the mixture incubated at 37 °C overnight. To select for transconjugants, serial dilutions of the cultures were plated on MacConkey agar containing ceftazidime (4 μg/ml) and sodium azide (100 μg/ml), which medium is toxic to donor cells. Confirmation of transfer was determined by PCR as described above to detect *bla*~VIM~ among transconjugants.

Quality control {#Sec9}
---------------

Well-characterized carbapenemase producing clinical strains of *Klebsiella pneumoniae* (Nr.8) and *Pseudomonas aeruginosa* from our collection \[[@CR1], [@CR9]\] were used as positive controls in molecular assays. For each gene that was PCR- amplified, PCR products were randomly selected and sequenced, and sequences confirmed through BLAST-searching at the National Centre for Biotechnology Information (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) as previously described \[[@CR1]\]. 'No template' PCR controls and negative control PCRs with template DNA extracted from carbapenemase gene negative strains (*K. pneumoniae* DSMZ 9377, *E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853) were also included \[[@CR1]\].

Results {#Sec10}
=======

A total of 9269 specimens from various wards at Mulago Hospital yielded 1077 and 488 isolates of *Acinetobacter baumannii* and *Pseudomonas aeruginosa*, respectively. Altogether, 2.7% (29/1077) and 7.4% (36/488) isolates were confirmed to be CRAB and CRPA respectively, Table [1](#Tab1){ref-type="table"}. Acinetobacter species were detected in virtually all the tracheal aspirate samples and most of these samples yielded poly-microbial isolates that included *Klebsiella pneumoniae* and *Escherichia coli*. Table 1Clinical specimens from which CRAB and CRPA were recoveredSpecimen typeNo. of specimens*Acinetobacter* species*Pseudomonas aeruginosa*No. isolated (%)No. CRAB reported (%)No. CRAB recoveredNo. isolated (%)No. CRPA reported (%)No. CRPA recoveredBlood7343412 (5.6)4 (0.97)2127 (1.72)00Sputum908119 (13.1)1 (0.84)173 (8.03)7 (9.6)4Pus swab3507 (2)005 (1.2)4 (80)4Tracheal aspirate221344 (155.7)11 (3.2)10207 (93.7)15 (7.2)10Ear swab177117 (66.1)7 (5.98)413 (7.3)2 (15.4)2Throat swab16013 (8.1)3 (23)113 (8.1)3 (23.1)1Catheter tip9458 (61.7)1 (1.7)145 (47.9)5 (8.9)4BAL fluid167 (43.8)2 (28.6)25 (41.3)00Total92691077 (11.6)29 (2.7)21488 (5.3)36 (7.4)25*BAL* Broncho-alveolar lavage fluid, *CRAB* Carbapenem resistant *Acinetobacter baumannii*, *CRPA* Carbapenem resistant *Pseudomonas aeruginosa*

CRAB and CRPA isolates recovered per year and hospital ward {#Sec11}
-----------------------------------------------------------

The CRPA isolates recovered in 2015, 2016 and 2017 were 8/21 (38%), 4/21 (19%) and 9/21 (43%), respectively: The yield per ward (ICU & ENT) was five & three isolates (2015); three & one isolate (2016); eight & one isolate (2017), respectively. Furthermore, the CRAB isolates recovered in 2015, 2016 & 2017 were 6/25 (24%), 3/25 (12%) and 16/25 (64%), respectively: The yield per ward was four & two in 2015 from ICU & ENT, respectively; three in 2016 from ICU; 13, two & one in 2017 from ICU, ENT & Burns Unit, respectively.

Carbapenemase activity among CRAB and CRPA isolates {#Sec12}
---------------------------------------------------

Carbapenemase assays performed with the MHT assay showed that 40% (10/46) and 33% (15/46) of CRPA and CRAB isolates respectively, were positive for carbapenemase production. Furthermore, 72% (18/46) and 48% (10/46) of CRPA and CRAB isolates respectively, were MBL producers and none was positive for KPC, Table [2](#Tab2){ref-type="table"}. Table 2Carbapenemase activity among CRPA and CRAP isolates (*n* = 46)MHTMHT (%)MBL activityEDTA-DST (%)IMP hydrolysis (%)MEM hydrolysis (%)KPC (*n* = 28)KPC (%)+ve-ve+ve-ve+ve-ve+ve-ve+ve-veCRPA (25)10 (40)15 (60)CRPA (25)18 (72)7 (28)25 (100)021 (84)4 (16)CRPA (10)00CRAB (21)7 (33)14 (67)CRAB (21)10 (48)11 (52)21 (100)021 (100)0CRAB (18)00Total: 461729462818464242800*CRPA* Carbapenem resistant *Pseudomonas aeruginosa*, *CRAB* Carbapenem resistant *Acinetobacter baumanii*, *EDTA-DST* EDTA disk synergy test, *IMP* Imipenem, *MEM* Meropenem, *KPC Klebsiella pneumoniae* carbapenemase, *+ve* Positive, *−ve* Negative

Prevalence of carbapenemase genes and class 1 integrons {#Sec13}
-------------------------------------------------------

*bla*~VIM~ was the most prevalent carbapenemase gene and it was detected in all CRPA and CRAB isolates, Table [3](#Tab3){ref-type="table"}. Of note, the other MBL encoding genes i.e. *bla*~IMP~, *bla*~SPM,~ and *bla*~NDM~, were not detected; as well, carriage of the OXA-type carbapenemase genes was not detected in CRPA. Also, in agreement with activity assays, none of our isolates was positive for *bla*~KPC~ carriage. We however found the OXA-type carbapenemase genes to be prevalent among CRAB i.e. 29% & 24% for *bla*~OXA-23~ & *bla*~OXA-24~, respectively. Co-carriage of *bla*~OXA-23~ and *bla*~OXA-24~ was seen in 14% of the CRAB isolates. All CRAB isolates carried the *bla*~OXA-51~ gene while none carried *bla*~OXA-58~. Class 1 integrons of sizes 500 bp to 1000 bp were detected in 63% (29/46) of the isolates: 64% (16/25) & 62% (13/21) CRPA & CRAB respectively, Table [3](#Tab3){ref-type="table"}. Furthermore, the classification of *Acinetobacter baumanii* based on *bla*~OXA-51~ gene sequences \[[@CR20], [@CR21]\] showed that 12, eight and one CRAB isolate in this study belonged to pan-European International Clones II, I & III, respectively. Table 3Prevalence of class 1 integrons among *bla*~VIM~-positive isolatesNo. screenedNo. (%) with *bla*~VIM~No. (%) with *bla*~VIM~ + class 1 integronPositiveNegativePositiveNegativeCRPA (25)25 (100)0 (0)16 (64)9 (36)CRAB (21)21 (100)0 (0)13 (62)8 (38)

All the *bla*~OXA-23~-positive isolates were detected in samples from the ICU; these were tracheal aspirates and sputum samples -tracheal aspirates provided 83% of *bla*~OXA-23~ positive CRAB while sputum samples yielded 17%. Likewise, 80% of *bla*~OXA-24~ positive CRAB isolates were detected in tracheal aspirates from the ICU. All isolates with co-carriage of *bla*~OXA-23~ and *bla*~OXA-24~ genes were detected in tracheal aspirates from the ICU. Only 20% of the *bla*~OXA-24~ positive CRAB isolates were from the ENT ward.

Drug susceptibility profiles of CRAB and CRPA isolates {#Sec14}
------------------------------------------------------

*bla*~VIM~-plus-*bla*~OXA~ positive CRAB exhibited high levels of resistance to commonly used antibiotics especially ceftazidime (100%), gentamicin (88%), ciprofloxacin (88%), cefepime (75%), piperacillin/tazobactam (63%), and amikacin (50%), Table [4](#Tab4){ref-type="table"}. Most of the CRAB and CRPA isolates were MDR (resistance to three or more classes of antimicrobials) however, all were susceptible to colistin. Furthermore, the susceptibility profiles of isolates carrying a single OXA-type gene (either *bla*~OXA-23~ or *bla*~OXA-24~) were not different from profiles of isolates that carried two genes concurrently. Table 4Susceptibility profiles of CRAB carrying both *bla*~OXA-23~-like and *bla*~OXA-24~-like genesIsolate No.Year of isolationIMPMEMCNPTZCAZAKFEPCIPCT42682015RRRRRRRRS29322015RRRRRRSRS46432015RRRIRSIRS1566.32015RRSRRSRRS15662016RRRIRSRIS2753.12016RRRIRIRRS4264.22017RRRRRRRRS4264.12017RRRRRRRRS% R10010088631005075880*IMP* Imipenem, *MEM* Meropenem, *CN* Gentamicin, *PTZ* Piperacillin/tazobactam, *CAZ* Ceftazidime, *AK* Amikacin, *FEP* Cefepime, *CIP* Ciprofloxacin, *CT* Colistin, *R* Resistant, *I* Intermediate, *S* Susceptible. 4264.2, 4268 & 4264.1 carried both *bla*~OXA-23-like~ & *bla*~OXA-24-like~ genes

Similarly, *bla*~VIM~-positive CRPA isolates showed high level resistance to gentamicin (100%), ceftazidime (89%), amikacin (72%), cefepime (72%), piperacillin/tazobactam (56%) and ciprofloxacin (50%); 94% of the isolates were MDR but susceptible to colistin. As well, all CRAB and CRPA isolates that were positive for both *bla*~VIM~ and class 1 integrons were highly resistant to the tested antibiotics but the susceptibility profiles were not different from isolates that did not carry class 1 integrons, Table [5](#Tab5){ref-type="table"}. Table 5Susceptibility profiles of CRAB and CRPA positive for *bla*~VIM~ plus class 1 integronsIsolate No.Year of isolationCarbapenem resistant *Acinetobacter baumanii*IMPMEMCNPTZCAZAKFEPCIPCT4268^a^2015RRRRRRRRS2932^a^2015RRRRRRSRS4643^a^2015RRRIRSIRS1566.3^a^2015RRSRRSRRS2932.2^a^2015RRIIRSSRS4722.12015RRIIRSRIS5730.2^a^2015RRRIRRRIS1566^a^2016RRRIRSRIS2753.12016RRRIRIRRS1688^a^2016RRRIRSIIS2026.22016RRRSISIIS4264.2^a^2017RRRRRRRRS4264.1^a^2017RRRRRRRRS4725.12017RRRIRSIRS2987.1^a^2017RRRIISSSS35232017RRRRRSRRS4725.22017RRRRRRRRS1314.12017RRRIRRRRS1314.22017RRSIRSRRS% R^a^1001008246914655550% R1001007937904263630Carbapenem resistant *Pseudomonas aeruginosa* 47862015RRRIRRRIS 5730^a^2015RRRIRRRIS 3361^a^2015RRRRRRRRS 0620^a^2015RRRIRSSIS 6797^a^2016RRRRRRIRS 1688.2^a^2016RRRIRRRIS 0004.12017RRRRRRRIS 3512^a^2017RIRRSRRRS 31682017RRRIRSRIS 18642017RRRRRRIIS 0466.2^a^2017RRRRRRRRS 0004.2^a^2017RRRIRRRRS 0466.1^a^2017RRRRRRRRS 0903^a^2017RRRRRSRRS 3337.1^a^2017RRRRRRRRS 3337.2^a^2017RRRRRRRRS 0921^a^2017RRRIISSSS 34762017RRRIRSSIS% R^a^1009210062857777690% R1009410056897272500^a^*bla*~VIM~ plus class 1 integron positive isolates; *IMP* Imipenem, *MEM* Meropenem, *CN* Gentamicin, *PTZ* Piperacillin/tazobactam, *CAZ* Ceftazidime, *AK* Amikacin, *FEP* Cefepime, *CIP* Ciprofloxacin, *CT* Colistin, *R* Resistant, *I* Intermediate, *S* Susceptible

Transfer experiments {#Sec15}
--------------------

To demonstrate the potential for mobility of carbapenemase encoding genes in the hospital environment, conjugation experiments were successfully performed. Donors were CRPA and CRAB isolates that were positive for both *bla*~VIM~ and class 1 integrons while the recipient was sodium azide resistant *E. coli* strain J53*.* PCR assays showed that 25 and 39% of CRPA and CRAB donors respectively, successfully transferred the *bla*~VIM~ genetic element to *E. coli*, Additional file [1](#MOESM1){ref-type="media"}: Figure S1.

Discussion {#Sec16}
==========

Antimicrobial drug resistance (AMR) is a well-recognized global problem and high rates of resistance to first-line antibiotics among Gram-negative bacteria have been reported in Uganda \[[@CR22]\]. As such, routine surveillance studies are necessary to monitor antibiotic resistance trends in low-income countries where antibiotic selection pressure is likely to be high.

This study has revealed that the prevalence of CRAB and CRPA in clinical specimens from Mulago Hospital remains relatively low and comparable to recently reported rates for carbapenem resistant Gram negative bacteria in Uganda \[[@CR1], [@CR9], [@CR23]\]. Importantly, almost all the CRAB and CRPA isolates were from the ICU. Furthermore, *bla*~VIM~ and *bla*~OXA-23~ were the most prevalent carbapenemase genes with the former being detected in all CRAB and CRPA isolates. As such, *bla*~VIM~ and *bla*~OXA-23~ are the genes mediating carbapenem resistance in CRAB and CRPA in the Mulago Hospital ICU. Again, these findings are consistent with a recent study at Mulago Hospital and other settings in developing countries where similar studies have been done \[[@CR1]--[@CR3], [@CR9], [@CR24]\]. In addition to the *bla*~VIM~ gene, we also detected *bla*~OXA-23~, *bla*~OXA-24~ and *bla*~OXA-51~ genes in CRAB. Unlike *bla*~OXA-23~- and *bla*~OXA-24~-like genes, *bla*~OXA-51~ naturally occurs in *Acinetobacter baumannii* \[[@CR1], [@CR6], [@CR8]\]. Furthermore, while in the previous study at Mulago \[[@CR1]\] the detection of *bla*~OXA-58~-like gene in CRAB was reported, it was not detected in this study. However, this observation is in agreement with studies by Minandri et al. 2011 \[[@CR25]\] and Wu et al. 2015 \[[@CR26]\] who discussed the transition from carriage of *bla*~OXA-58~-like to *bla*~OXA-23~-like and *bla*~OXA-24~-like genes. Furthermore, through conjugation experiments we demonstrated the potential for horizontal gene transfer of the *bla*~VIM~ gene. Transfer rates in our study were low but in agreement with another study \[[@CR27]\] which reported similar transfer rates. We have therefore provided evidence suggestive of mobility for carbapenem resistance genes in the Mulago hospital environment via horizontal gene transfer processes.

Although CRAB and CRPA that simultaneously carried *bla*~VIM~ and class 1 integron were highly resistant to antibiotics, the susceptibility profiles were not different from isolates that did not carry class 1 integrons. Hence, carriage of integrons did not affect the resistance profiles implying that integrons in these isolates either did not carry drug resistance genes or they carried cassettes encoding resistance phenotypes that were not screened for. Furthermore, the susceptibility profiles of CRAB carrying a single OXA-type gene (either *bla*~OXA-23~ or *bla*~OXA-24~) were not different from profiles of isolates that carried two genes concurrently. As *OXA* genes generally confer a β-lactam resistance phenotype, the additive effect might be better detected with minimum inhibition concentrations (MICs), not agar diffusion approaches we used.

Additionally, although the CRAB and CRPA isolates we investigated were not associated with outbreaks, their detection in clinical specimens is of public health significance. Indeed, we observed high resistance to common antibiotics but this has been reported before \[[@CR1], [@CR2], [@CR26]\]. Of note, carriage of *bla*~OXA-23~ alone, or *bla*~OXA-23~ plus *bla*~OXA-24~ in bacteria has been associated with high resistance to carbapenems and to other classes of antimicrobials \[[@CR25], [@CR26]\]. While *bla*~VIM~ carriage in this setting has been reported before \[[@CR3], [@CR28], [@CR29]\], a high prevalence of *bla*~VIM~ is worrying as this genetic element renders carbapenems (imipenem & meropenem) ineffective \[[@CR3], [@CR29]--[@CR31]\], narrowing treatment options to colistin & polymyxin B that have been associated with drastic side effects e.g. nephrotoxicity, neurotoxicity, etc. \[[@CR3], [@CR29]--[@CR31]\]. As such, a narrow window remains before total antimicrobial resistance is seen in these bacterial isolates as they continue to be subjected to antibiotic pressure in the hospital \[[@CR32]--[@CR35]\]. Unlike in the previous study \[[@CR1]\] we did not detect the three MBL genes *bla*~SPM~, *bla*~NDM~ *and bla*~IMP~ that have been associated with high resistance to carbapenems especially to imipenem \[[@CR36], [@CR37]\]. Further, the high prevalence of *bla*~VIM~ in CRAB and CRPA in this study is suggestive of the role of the accessory genome in evolution of carbapenem resistance in our setting. *bla*~VIM~ is characterized as an acquired MBL gene translocated between bacteria via class 1 integrons, in horizontal gene transfer mechanisms mostly involving conjugative plasmids \[[@CR28], [@CR38]--[@CR40]\].

There were certain limitations in this study. We screened isolates for colistin susceptibility using the agar diffusion method instead of the recommended broth microdilution or the Etest methods. Further studies should take this into consideration given that poor agar dilution characteristics can limit the predictive accuracy of the disk diffusion method.

Conclusions {#Sec17}
===========

*bla*~VIM~ and *bla*~OXA-23~ are the most prevalent carbapenemase genes among CRAB and CRPA isolates at the Mulago Hospital ICU. There is need to improve infection control practices at the hospital to curb the transmission of the isolates in the hospital.

Supplementary information
=========================

 {#Sec18}

**Additional file 1:** **Figure S1.** A representative image showing donors and trans-conjugants screened for presence of *bla*~VIM~ gene. Lanes: L, 100 bp DNA ladder; D, 382 bp *bla*~VIM~ fragment in donors (CRAB or CRPA isolate); T, 382 bp *bla*~VIM~ fragment in trans-conjugant (*E. coli* J53, recipient); P, *bla*~VIM~ carrying strain (positive control); J53, unconjugated *E. coli* J53 (negative control recipient).
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